Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis

Next Previous
Search
Trial Profile

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegbelfermin (Primary)
  • Indications Hepatic fibrosis; Liver cirrhosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms FALCON 2
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 14 Nov 2023 Results of post-hoc exploratory analysis comparing FibroNest's continuous scores with NASH-CRN categorical stages in patients with NASH, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
  • 14 Nov 2023 Results obtaining biopsy slide from NCT03486899and NCT03486912, investigating the possibility to overcome this limitation using multi parametric measurements like Somalogic (a biomarker) and qFibrosis (AI histology), presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
  • 08 Mar 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top